Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Summary
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s pr...
Description
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s pr...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source